# Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

> **NCT03248479** · PHASE1 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 258 (actual)

## Conditions studied

- Hematological Malignancies

## Interventions

- **DRUG:** Magrolimab
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT03248479
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-08
- **Primary completion:** 2023-09-05
- **Final completion:** 2023-09-05
- **Target enrollment:** 258 (ACTUAL)
- **Why stopped:** This study has been discontinued due to futility based on the results of a planned analysis of the ENHANCE trial.
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03248479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03248479, "Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03248479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*